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ABSTRACT 
Background: Chronic kidney disease has emerged as one of the primary co-morbid 
conditions affecting human immunodeficiency virus infected individuals even after highly-
active antiretroviral therapy. 
Objectives: To assess chronic kidney disease and associated factors among highly active 
antiretroviral therapy naïve and experienced HIV infected individuals at the University of 
Gondar Hospital, Gondar, Northwest Ethiopia.   
Method: A Hospital based comparative cross-sectional study was carried out at the 
University of Gondar Hospital from March to May, 2017. Double population proportion 
formula and convenient sampling technique were used to select 250 study participants. 
Socio-demographic and clinical data were collected by using pretested semi-structured 
questionnaire. The collected data were entered into Epi-Info version 3.5.1 and analyzed using 
SPSS version 20.  Descriptive statistics, independent t-test, bivariable and multivariable 
logistic regression analysis were performed. A p-value of <0.05 was considered as 
statistically significant.  
Result: From a total of 250 study participants, 125 were highly active antiretroviral therapy 
naïve and 125 were experienced. Of the total, 67.2% were females. The mean (±SD) age of 
the HAART naïve and experience individuals were 35.0(±9.5) and 45.0(±9.9) years, 
respectively. The overall prevalence of CKD among HIV infected study participants was 
13.2%. The prevalence of CKD in HAART naïve and HAART experienced individuals was 
15.2% and 11.2%, respectively. Age ≥ 50 years and CD4 count <200cells/mm3 were 
statistically significant among HAART naïve participants. TDF regimen and CD4 count < 
200 cells/mm
3
 were statistically significant among HAART experienced participants.  
Conclusion and recommendation: The prevalence of CKD was higher among HAART 
naïve than HAART experienced HIV infected individuals. CKD was associated with higher 
age, low CD4 count and TDF regimen users. A renal function assessment should be done 
before and during HAART to reduce renal dysfunction.  
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1. INTRODUCTION 
1.1 Background 
The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune 
system, destroying or damaging their function. HIV 1 and 2 are the primary cause of 
acquired immunodeficiency syndrome (AIDS). HIV-1 is the major cause of AIDS in the 
world (1). 
After global treatment goal was began in 2003, annual AIDS-related deaths have decreased 
by 43%. Global coverage of antiretroviral therapy (ART) reached 46% at the end of 2015. 
Eastern and Southern Africa are the most affected region by ADIS related death in the world.  
In these region ART coverage enlarged from 24% in 2010 to 54% in 2015, reaching a total of 
10.3 million people (2). 
Renal disorders in HIV patients is noticeable ranging from fluid and electrolyte imbalances 
to end stage renal disease (ESRD) regardless of HIV stages. Treatment-related factors, 
recurrent viremia, and traditional risk factors may be attributable for chronic kidney disease 
(CKD)  (3). 
Renal function impairment that results from HIV infection is called human 
immunodeficiency virus associated nephropathy (HIVAN) which is predominantly prevalent 
in black people specially sub-Sahara population (4, 5). Antiretroviral (ARV) drugs can also 
result renal damage which is presenting as acute kidney injury, tubular necrosis, kidney 
stones, or CKD (4, 6).  
Renal toxicity associated with the use of nucleoside analogues is generally rare. Case reports 
have demonstrated that didanosine and lamivudine-stavudine treatment have been associated 
with tubular dysfunction (7, 8). 
Tenofovir and cidofovir are acyclic nucleoside phosphonates that have been associated with 
renal tubular damage. The renal adverse effects may cause a variety of clinical presentations 
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varying from tubule cell death, such as acute tubular necrosis, to possibly reversible tubular 
dysfunction (9).   
Tenofovirdisoproxil fumarate (TDF) is nucleotide analog reverse transcriptase inhibitor 
(NRTI), and may be associated with its tubular damage representing mitochondrial 
dysfunction (10).  
TDF can decreased glomerular filtration rate, including Fanconi syndrome, also known as 
multiple tubular dysfunction syndrome, manifested as renal glucosuria, amino acids, urine, 
hypercalciuria, renal failure, and other renal toxicity, the renal toxicity has been widespread 
concern, now on the TDF in the HIV/AIDS (11).  
HAART regimens containing the combination tenofovir/atazanavir is associated with low 
estimated glomerular filtration rate which leads to increase risk of CKD development (12). 
Generally, renal system excrete many drug and their metabolites through the proximal tubule. 
So that drug related damage can be occurred because of the presence of high rate of blood 
flow with high level of toxin via proximal tubule (10). 
The current study was intended to assess CKD and related factors both in HAART naïve and 
HAART experienced HIV infected patients at the University of Gondar Hospital, Northwest 
Ethiopia. 
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1.2. Statement of the problem 
The introduction of highly active antiretroviral therapy has led to noticeable reduction in 
HIV-related mortality (13). However, renal disease is becoming an increasingly prevalent co-
morbidity and mortality in patients with HIV infection. The increase in life expectancy 
following the introduction of HAART and the long term development of metabolic 
complications such as diabetes and dyslipidemia, hypertension, and vascular diseases can 
contribute to the increasing frequency in the recognition of renal impairment in HIV-infected 
patient (14).  
A 4% to 17% prevalence of reduced kidney function in diverse HIV-infected populations 
was reported (15-17).  Reports from different countries demonstrated that the occurrence of 
CKD with HIV infection was significantly high. For instance, 5.6% in Brazil, 18% in 
Switzerland, 27% in India, 12.3% in Iran, (18).  
The contribution of HIV/AIDS to the prevalence of CKD in North-Central zone of Nigeria 
was as high as 47.6% (19). Using different criteria for diagnosis of CKD, different scholars  
reported a high burden of CKD in patients with HIV in different Africa countries; South 
Africa (6% ), Nigeria (38%), Côte d’Ivoire (26%), Zambia (33.5%), Tanzania (28%), Uganda 
(20–48.5%), and Kenya (25%) (20). 
The burden of CKD in HIV patients was reported in Southwest (18.2%) and Northwest 
(21.5% and 11.7%) of Ethiopia (21-23).  
The presence of CKD in HIV patients will lead to death even if they take Antiretroviral 
therapy (24). Individuals with CKD are more likely to experience drug adverse effects with 
protease inhibitors (25).  Renal disease in HIV-infected individuals, is a contributing factor 
for morbidity and mortality (26).   
Risk factors associated with CKD in HIV-infected populations include aging, female gender, 
hypertension, diabetes mellitus, low CD4 cell count, and ART exposure (16, 27, 28).   
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2. LITERATURE REVIEW 
At all stages of HIV infection, renal disorders may be evident, ranging from fluid and 
electrolyte imbalances to end stage renal disease (3). ARV drugs can result renal damage 
which is presenting as acute renal failure, tubular necrosis, kidney stones, or CKD (4, 6).  
A retrospective observational analysis in a total of 5905 participants using the clinical 
database of a large center in Institute of Tropical Medicine in the urban area of Antwerp, 
Belgium showed that the prevalence of CKD among HIV infected subjects was found to be 
3.0%. The development of CKD was associated with age above 50 years and lower CD4 cell 
counts (29). 
According to a cross sectional study done in Brazil with 198 patients revealed that CKD was 
diagnosed in 8.4% of the population. The factors significantly associated with CKD were 
hypertension, time on HAART and tenofovir exposure (30).   
A similar study done in a total of 322 Chinese HIV-infected participants indicated that the 
prevalence of CKD and proteinuria was 16.8%and 2.6%, respectively and 5.6% had GFR 
less than 60 ml/min/1.73 m
2
. Older age and use of indinavir therapy were associated with 
development of CKD (16). 
Likewise, another multicenter cross-sectional study done in Mainland, China in 538 HIV-
infected ART-naïve patients revealed that the prevalence of CKD 16.1%. As stated by this 
study, 13.7% patients had proteinuria. According to this study older age, hypertension, and 
were signiﬁcantly associated with CKD (31).  
Alternative cross sectional study conducted in Kwara state, Nigeria with 183 treatment-naive 
HIV-infected patients revealed that 24% patients had CKD. The eGFR, 12% patients had 
stage 1, 63.9% stage 2, 7.1% stage 3, 14.8% stage 4, and 2.`2% stage 5 CKD (32).   
In a similar cross-sectional study of 227 newly diagnosed, ARV naïve patients with 
HIV/AIDS carried out in Ilorin, Nigeria indicated that CKD was observed in 47.6% among 
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the patients and 16.7% of the controls. Forty one percent of the patients had dipstick 
proteinuria of ≥ 2 + (19). 
A multicenter cross-sectional survey was carried out at Burundi in 300 patients revealed that 
CKD prevalence in patients was 45.7%. According to this study, 30.2% of whom being 
classified as stage 1, 13.5% as stage 2 and 2% as stage 3. No patient was classified as stage 4 
or 5. Among CKD patients with urinary abnormality, proteinuria accounted for 6.1% and 
leukocyturia for 18.4%. Significant associations were found between leukocyturia, previous 
history of tuberculosis, low BMI and female gender (33).  
According to cross-sectional observational study conducted in Nairobi, Kenya showed that 
evidence of CKD was seen in 88% of patients; 17.6% had eGFRCKD and 86.3% had 
albuminuria and no preselected risk factors were found to have significant association with 
presence of CKD (34).  
A facility based comparative cross-sectional study conducted in 446 HIV positive individuals 
in Jimma, Ethiopia showed that the overall prevalence of renal function impairment was 
18.2%. The prevalence of renal impairment in HAART naïve and HAART experienced 
persons was 28.7% and 7.6%, respectively. Age ≥ 50 years and advanced WHO stage were 
independent risk factors among HAART naïve participants. Female gender and age ≥50years 
were independent risk factors among HAART experienced participants. There was no 
difference between glucose level of HAART naive and HAART experienced participants 
(21). 
A similar study was conducted among 307 HIV positive patients at Bahir Dar, Ethiopia 
showed that the prevalence of renal impairment in HAART naïve and on HAART 
individuals was 30.1% and 12.9% respectively. As stated by this study the average serum 
creatinine concentration and BUN were higher and mean creatinine clearance was lower in 
HAART naïve individuals compared with those individuals who were on HAART. It was 
also found that higher age, lower CD4 count, advanced in WHO clinical stage and being 
HAART naïve were associated with moderate to severe renal impairment. In HAART 
experienced individuals only low CD4 was found to be the independent risk factor (22). 
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A similar study was conducted in 275 study subjects in Gondar, Ethiopia indicated that the 
overall prevalence of CKD HAART treatment naive and on HAART treatment was 3.6% and 
11.7%, respectively. According to this study a majority of the CKD patients were in stage 3 
for patients on HAART treatment than HAART treatment naive. 3.1% of the patients had 
renal failure HAART treatment than HAART treatment naive. Being female was a risk factor 
for CKD (23). 
Generally the prevalence of CKD in HAART naive and HAART treatment presence in 
different magnitude both in developed and developing countries. There may be different 
factors and different magnitudes based on different study design used, sample size, ethnicity, 
sex, age, definition of CKD, selection of formula for eGFR. Thus the aim of this study was to 
assess CKD and associated factors among HAART Naïve and HAART Experienced adult 
HIV positive individuals at the University of Gondar Hospital, Northwest Ethiopia.  
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3. SIGNIFICANCE OF THE STUDY 
HIV affects all parts of the world, but sub-Saharan Africa is the highest epidemic area. 
Ethiopia currently has high numbers of people affected by the problem.  
Chronic kidney disease becomes high and fast growing public health burden in HIV infected 
patients. Even though there is high disease burden of HIV in Ethiopia, we have limited data 
on HIV related kidney disease. Therefore, the purpose of this study is to assess chronic 
kidney disease among HIV infected patients attending at the University of Gondar Hospital. 
The findings will be supportive to early diagnosis and treatment of HIV related renal 
dysfunction. In addition, this study will give reliable information regarding associated factors 
which may increase the development of chronic kidney disease. It will be also helpful for 
clinicians to know associated factors to manage HIV/ADIS patients. This study may use as a 
reference for further studies. 
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4. OBJECTIVES OF THE STUDY 
4.1. General objective 
 To assess chronic kidney disease and associated factors among HAART naïve and 
HAART experienced HIV infected individuals at the University of Gondar Hospital, 
Northwest Ethiopia. 
4.2. Specific objectives 
 To determine the prevalence of CKD among HAART naïve and HAART experienced 
HIV infected individuals.  
 To identify the associated factors of CKD among HAART naïve and HAART 
experienced HIV infected individuals.  
 To compare mean of eGFR and creatinine level between HAART naïve and HAART 
experienced HIV infected individuals. 
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5. METHODS AND MATERIALS 
5.1. Study area 
The study was conducted at the University of Gondar Hospital ART clinic. The Hospital is 
located in North Gondar, Northwest Ethiopia around 747 km away from the capital city, 
Addis Ababa. The Hospital is one of the biggest Hospitals in north Gondar that provides 
health services and acts as the referral center for other district hospitals. It has over 400 beds 
including one ART clinic. The ART clinic gives service for a total of over 13,863 HIV 
infected individuals. 
5.2. Study design and period 
Hospital based comparative cross sectional study was conducted from March to May, 2017 to 
assess chronic kidney disease and associated factors among HAART naïve and HAART 
experienced HIV infected individuals attending at the University of Gondar Hospital. 
5.3. Population 
5.3.1. Source population 
All HIV infected HAART naïve and HAART experienced individuals who had access to be 
served at the University of Gondar Hospital ART clinic. 
5.3.2. Study population 
All HIV infected HAART naïve and HAART experienced individuals who visited the 
hospital during the study period and fulfill the eligibility criteria. 
5.4. Inclusion and exclusion criteria 
5.4.1. Inclusion criteria 
≥18 years old HIV infected HAART naïve and HAART experienced, Individuals ≥1 year 
since start ART. 
5.4.2. Exclusion criteria 
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Severely ill patients (unable to speak, admitted patients), pregnant women, >65 years, and 
amputees were excluded from the study. 
5.5. Study variable 
5.5.1. Dependent variable 
 Chronic kidney disease (CKD) 
5.5.2. Independent variables 
 Socio-demographic characteristics :- age, gender, religion, educational level, income, 
 Co-morbidity:- Diabetes mellitus, Hypertension, acute kidney disease, kidney stone, 
 HIV related characteristics:- Duration of HIV after diagnosis, ARV, CD4 count, 
Stage of HIV infection, regimen types, 
 Anthropometric measurements:- weight, height, BMI, 
 Laboratory tests: - Cr, Urea, Glucose, CrCl, eGFR, urine chemical tests (dipsticks). 
5.6. Operational definitions 
The eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) Study 
equation: 186 ×                    
  
  
        ×             × (0.742 if female) x (1.210) 
by using eGFRonline calculator.  
After calculating the eGFR, patients having CKD were classified into five stages of CKD 
according to the National Kidney Foundation – Kidney Disease Outcome Quality Initiative 
(KDOQI)classification system (35, 36)as follows:  
 Stage 1, persistent proteinuria with eGFR ≥ 90 ml/min/1.73 m2,  
 Stage 2, persistent proteinuria with eGFR of 60-89.9 ml/min/1.73 m2, 
 Stage 3, eGFR 30-59.9 ml/min/1.73 m2with or without proteinuria, 
 3A (eGFR 45–59.9ml/min/1.73 m2), 
 3B (eGFR 30–44.9ml/min/1.73 m2),  
 Stage 4, eGFR 15-29.9 ml/min/1.73 m2with or without proteinuria and  
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 Stage 5 (kidney failure), eGFR<15ml/min/1.73 m2 with or without proteinuria. 
Chronic kidney disease was defined as eGFR<60ml/min/1.73 m
2 
with proteinuria. 
HAART experienced persons who took HAART for more than 1 year which is composed of 
two NRTIs plus a NNRTI (37). 
5.7. Sample size  
The sample size was determined using double population proportion general formula by 
taking two different proportions of chronic renal disease (3.6%) for HAART naïve and 
(11.7%) for HAART experienced participants from the work done in Northwest of Ethiopia 
(23), taking a critical value at 95% confidence level, the level of significance 0.05 and Power 
(1-β) =90. By inserting these assumptions in to Epi-Info software the calculated sample size 
was 227, 113.5 for each group. By adding 10% compensation for non-respondents a total of 
250 individuals, 125 for each group, were selected and convenient sampling technique was 
used. 
N=              
  
 
            
=2(0.0765) (1-0.0765) (1.28×1.96)
2 
/ (0.036-
0.117)
2
 
= 2                             
                            0.006561  
= 226.0728  227 
= 227 10%, Assuming 10% non-respondent 
rate 
= 22.7  23, =227+23 
N =250 
Where    
 n= minimum sample size 
   = best estimate of double population 
proportion,             
 P1= proportion of CKD for HAART 
naïve= 3.6%   
 P2= proportion of CKD for HAART 
experienced= 11.7%  
 Zβ= Power (1-β) =90% = 1.28 
 Zα/2= level of significance 0.05 = 1.96
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5.8. Data collection and laboratory methods 
First, study participants were asked to fill the written consent form after pre-test was 
conducted in 5% of the study participants in Koladiba Hospital. Then Socio-demographic 
characteristics and clinical data were collected by trained nurses using semi-structured 
questionnaire. In addition, anthropometric and blood pressure measurement was taken by 
qualified personnel. 
Five milliliter of venous blood sample was collected in gel containing serum separator test 
tubes and then serum was separated after the sample was clotted and centrifuged by trained 
laboratory technologists. Biochemical analysis was done using Mindray BS-200 chemistry 
analyzer (Shenzhen Mindray Bio-Medical Electronics Co. Ltd, China) for creatinine, and 
urea level determination. Fifty milliliter of freshly voided urine was collected by clean, dry 
container then urine dipstick was determine by using reagent strip with in 30 minute of 
collection according to manufacturer instruction. 
5.9. Data management and quality Control 
The questionnaire was pre-tested in Koladiba Hospital for its accuracy and consistency prior 
to actual data collection. Appropriate one day training was given for data collectors about the 
objectivity and relevance of the study, confidentiality issues, study participants’ right, 
consenting, techniques of interview, and regarding laboratory test procedures and their 
quality control. Socio-demographic and clinical data were collected by two trained nurses 
under the supervision of investigators. The biochemical tests were performed by two senior 
medical laboratory technologists under the supervision of principal investigator. 
Furthermore, the investigator was closely followed up and frequently check the data 
collection process to ensure the completeness and consistency of the collected data and also 
give feedback on a daily basis to the data collectors. Completion, accuracy, and clarity of the 
collected data was checked carefully on a regularly basis.  
The sample was processed within 1 hour of specimen collection in Clinical Chemistry 
Laboratory and processed based on the manufacturer’s manual. Normal and abnormal 
controls were run daily in order to check the optimal reactivity of the reagent and 
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functionality of the machine. The values obtained for controls must be within ± 2SD of the 
given range. Coefficient of variation must be <5%. Moreover, to maintain the quality of the 
result, pre-analytical, analytical and post analytical pre-cautions of quality depending on the 
stated SOP was considered and quality control results were interpreted using Levy Jenny 
chart and appropriate remedies was taken in case of unacceptable quality control results. 
5.10. Data analysis 
The Data was checked, cleaned, sorted, and categorized manually. Then, the data was entered 
to Epi info version 3.5.1 and then transferred to SPSS version 20 for analysis. Descriptive 
statistics, independent t test, bivariable and multivariable logistic regression analyses was 
performed. The multivariable model incorporated a backward and stepwise elimination 
method using variables with a P-value of <0.25 from the bivariable analysis. OR with95%CI 
were also obtained. All analyses were performed using SPSS version 20.0.A p value < 0.05 
was considered to be statistically significant.  
5.11. Ethical consideration 
Before starting the study, ethical clearance was obtained from Research and Ethical Review 
Committee of School of Biomedical and Laboratory Sciences, College of Medicine and 
Health Sciences, University of Gondar and the acquiescence was also obtained from the 
study institutions (University of Gondar Hospital). Full clarification about the purpose of the 
study was made to the Authorized persons of the Hospital. Permission letter was also taken 
from the clinical director of the Hospital and head of the ART clinic. To ensure 
confidentiality of the study participant’s information, anonymous typing was applied so that 
the name of the participant and any identifier of participants was not written on the 
questionnaire. Data was collected after full written consent obtained from each participant. 
The data were not used for another purpose. 
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5.12. Result dissemination 
This study on completion could serve as a reference material for researchers, experts and 
policy makers for intervention. To reach these bodies a copy of completed paper were 
submitted to the University of Gondar, College of Medicine and Health Sciences, School of 
Biomedical and Laboratory Sciences, Department of Clinical Chemistry and University of 
Gondar Hospital.  
 The result will also be disseminated through publication in peer reviewed local and 
international journal and through presenting it in related annual scientific meetings, 
conferences and seminars. 
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6. RESULT 
6.1. Socio demographic characteristics of study participants 
From a total of 250 HIV infected study participants, 168 (67.2%) were females. The mean 
(±SD) age of the study participants was 35 (±10) years and 45 (±10) years for HAART naïve 
and experienced patients, respectively. Majority (85.6%) were urban inhabitant, 56.4% were 
married and 28% of them were unable to read and write. During the study, 18.8% and 11.2% 
of study participants were alcohol drinkers and cigarette smokers, respectively (Table 1).  
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Table 1: Socio-demographic characteristics of HIV infected participants attending at the 
University of Gondar Hospital, Gondar, Northwest Ethiopia, 2017 (N=250). 
Variables HAART naive On HAART Total 
No (%) No (%) No (%) 
Age (years) 18-28 37(29.6) 1(0.8) 38(15.2) 
29-38 47(37.6) 36(28.8) 83(33.2) 
 39-48 29(23.2) 46(36.8) 75(30.0) 
 ≥40 12(9.6) 42(33.6) 54(21.6) 
Sex  Male 47(37.6) 35(28.0) 82(32.8) 
Female 78(62.4) 90(72.0) 168(67.2) 
Religion  Christian  108(86.4) 109(87.2) 217(86.8) 
Muslim  17(13.6) 16(12.8) 33(13.2) 
Ethnicity  Amhara  116(92.8) 116(92.8) 232(92.8) 
Tigre  9(7.2) 9(7.2) 18(7.2) 
Residency Urban 106(84.8) 108(86.4) 214(85.6) 
Rural 19(15.2) 17(13.6) 36(14.4) 
 Marital status  Single  15(12.0) 11(8.8) 26(10.4) 
Married  73(58.4) 68(54.4) 141(56.4) 
Windowed  11(8.8) 31(24.8) 42(16.8) 
Divorced  26(20.8) 15(12.0) 41(16.4) 
Educational level Unable to read and write  30(24.0) 40(32.0) 70(28) 
Primary  47(37.6) 37(29.6) 84(33.6) 
Secondary  32(25.6) 31(24.8) 63(25.2) 
Higher  16(12.8) 17(13.6) 33(13.2) 
Occupation  Unemployed  53(42.4) 39(31.2) 92(36.8) 
Self employed  50(40.0) 58(46.4) 108(43.2) 
Governmental  22(17.6) 28(22.4) 50(20) 
Smoking habit  No  107(85.6) 115(92.0) 222(88.8) 
Yes  18(14.4) 10(8.0) 28(11.2) 
Alcohol habit  No  81(64.8) 122(97.6) 203(81.2) 
Yes  44(35.2) 3(2.4) 47(18.8) 
Note: - HAART = Highly Active Anti-Retroviral Therapy, HIV= Human Immunodeficiency Virus 
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6.2. Clinical related information among HIV infected study participant 
About 51.2% of HIV infected study participants were found in WHO stage II. Less than half 
(45.6%) of HAART naïve and 67.2% of HAART experienced study participants were found 
in WHO stage III and stage II respectively. Almost all (98.4%) of HAART experienced study 
participants were receiving first line ART regimen. More than half (54.4%) of HAART 
experienced study participants were non TDF regimen users. Majority of (94.4%) HAART 
naïve study participants were <5 years since diagnosis of HIV. On the other hand, over half 
(52.8%) of HAART experienced participants were between 5-10 years since after diagnosis 
of HIV (Table 2).  
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Table 2: HIV related information among HIV infected participants at the University of 
Gondar Hospital, Gondar, Northwest Ethiopia, 2017 (N=250). 
Variables  HAART naïve On HAART Total 
No (%) No (%) No (%) 
Time since diagnosis  
of HIV (years) 
<5 118(94.4) 40(32.0) 158(63.2) 
5-10 7(5.6) 66(52.8) 73(29.2) 
>10 0(0) 19(15.2) 19(7.6) 
WHO HIV stage  I 13(10.4) 17(13.6) 30(12) 
II 44(35.2) 84(67.2) 128(51.2) 
III 57(45.6) 23(18.4) 80(32) 
IV 10(8.0) 1(0.8) 12(4.8) 
V 1(0.8) 0(0) 1(0.4) 
CD4+ (cells/mm
3
) <200 58(46.4) 28(22.4) 86(34.4) 
200-350 42(33.6) 38(30.4) 80(32) 
>350 25(20.0) 59(47.2) 84(33.6) 
Time since on ART (years) <5  
 
48(38.4)  
5-10 35(28.0)  
>10 42(33.6)  
ART regimen  First   
 
123(98.4)  
Second  2(1.6)  
 
First line regimen types  
1c  
 
 
47(37.6)  
1d 20(16.8)  
1e 48(38.4)  
1f 5(6.4)  
Note:-1c= AZT+3TC+NVP, 1d= AZT+3TC+EFV, 1e= TDF+3TC+EFV, 1f= TDF+3TC+ NVP= 3TC= 
lamivudine, AZT=zidovudine, NVP= nevirapine, EFV= efavirenz, TDF= Tenofovir Disoproxil Fumarate, 
CD4=Cluster of Differentiation4, WHO=World Health Organization, HIV= Human Immunodeficiency Virus, 
ART=Anti-Retroviral Therapy, HAART =Highly Active Anti-Retroviral Therapy. 
History of hypertension and diabetes mellitus were reported in 12(4.8%) and 11(4.4%) of the 
participants respectively. About 55.6% of study participants had a normal BMI (Table 3). 
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Table 3; Preselected risk factors among HIV infected study participants at the University of 
Gondar Hospital, Gondar, Northwest Ethiopia, 2017 (N=250). 
Variables  HAART naïve On HAART Total 
No (%) No (%) No (%) 
BMI (kg/m
2
) <18.5 37(29.6) 19(15.2) 56(22.4) 
 ≥18.5-24.9 61(48.8) 78(62.4) 139(55.6) 
 ≥25-29.9 25(20.0) 23(18.4) 48(19.2) 
 ≥30 2(1.6) 5(4.0) 7(2.8) 
Diabetes mellitus No  117(93.6) 122(97.6) 239(95.6) 
Yes  8(6.4) 3(2.4) 11(4.4) 
Blood pressure  No  115(92.0) 123(98.4) 238(95.2) 
Yes  10(8.0) 2(1.6) 12(4.8) 
Acute kidney injury  No  99(79.2) 97(77.6) 196(78.4) 
Yes  26(20.8) 28(22.4) 54(21.6) 
Kidney stone history  No  114(91.2) 118(94.4) 232(92.8) 
Yes  11(8.8) 7(5.6) 18(7.2) 
Note: - Body Mass Index (BMI), Acute Kidney Injury (AKI), HAART =Highly Active Anti-Retroviral 
Therapy, HIV =Human Immunodeficiency Virus  
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6.3. Renal function tests among HIV infected study participant 
The mean (±SD) of eGFR (MDRD) was 96.0 (± 44.8) ml/min/1.73 m
2 
and 85.3(±20.0) 
ml/min/1.73 m
2 
for HAART naïve study participants and for those who were HAART 
experienced, respectively. The mean (±SD) Cr level was 1.1 (±0.7mg/dl) for HAART naïve 
study participants and 0.98 (± 0.2 mg/dl) for those who were HAART experienced. 
Proteinuria 1+ and above was found in 34.4% and 47.2% of HAART naïve and HAART 
experienced study participants, respectively (Table 4). 
Table 4:Mean of biochemical parameters among HIV infected participants at the University 
of Gondar Hospital, Gondar, Northwest Ethiopia, 2017 (N=250). 
Parameters HAART naïve On HAART Total 
 Mean ±SD Mean ±SD Mean ±SD 
Cr (mg/dl)  1.1±0.7 0.98±0.2 1.04±0.45 
Urea (mg/dl) 18.5±15.0 19.4±10.1 18.95±12.55 
CrCl C-G (ml/min) 73.8±33.2 67.8±19.2 70.8±26.2 
eGFR(MDRD) (ml/min/1.73m
2
) 96.0±44.8 85.3±20.0 90.65±32.4 
CD4 (cells/mm
3
) 245.9±163.5 391.3±209.5 318.6±186.5 
Proteinuria Neg. 82(65.6) 66(52.8) 148(59.2) 
 1+
κ
 32(25.6) 39(31.2) 71(28.4) 
 2+ 11(8.8) 20(16.0) 31(12.4) 
Hematuria Neg. 101(80.8) 104(83.2) 205(82.0) 
 1+ 14(11.2) 16(12.8) 30(12.0) 
 2+ 10(8.0) 5(4.0) 15(6.0) 
Leucocytouria Neg. 96(76.8) 105(84.0) 201(80.4) 
 1+ 19(15.2) 16(12.8) 35(14.0) 
 2+ 10(8.0) 4(3.2) 14(5.6) 
Note: - =Based on single measurement, κ=30mg/dl on urine dipstick, HAART =Highly Active Anti-Retroviral 
Therapy, HIV =Human Immunodeficiency Virus, Cr =Creatinine, CrCl =Creatinine Clearance, eGFR 
=estimated Glomerular Filtration Rate, MDRD= Modification of Diet for Renal Disease, CD4= Cluster of 
Differentiation 4, Neg= Negative. 
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6.4. Comparison of biochemical and other variables between HAART naïve 
and experienced 
The mean (±SD) of Cr of HAART naïve and HAART experienced study participants was 
1.1±0.7 and 0.98±0.2, respectively (p =0.01). HAART naïve study participants had a 
significantly higher mean eGFR compared to the HAART experienced (96.0±44.8 
ml/min/1.7m
2
) vs (85.3±20.0 ml/min/1.73 m
2
); (p =0.01). Urea level, and CrCl, showed no 
signiﬁcant differences between HAART naïve and HAART experienced study participants. 
The mean (±SD) of CrCl in HAART naive study participants was 73.8±33.2 and the mean 
(±SD) of CrCl level among HAART experienced was 67.8±19.2 (p=0.08). The mean (±SD) 
BMI of the study participants was 21.0 (±4.0) and 22.0 (±4.0) for HAART naïve and 
HAART experienced study participants respectively; (p = 0.03). The mean (±SD) time since 
HIV diagnosis was significantly different between HAART naïve and HAART experienced 
participants (p value = 0.01) (Table 5).  
Table 5: Comparison of biochemical and other variables between HAART naive and 
HAART experienced individuals at the University of Gondar Hospital, Gondar, Northwest 
Ethiopia,2017 (N = 250). 
Parameters  HAART naïve On HAART p-value 
Mean ± SD Mean ± SD 
Cr (mg/dl) 1.1±0.7 0.98±0.2 0.01 
Urea (mg/dl) 18.5±15.0 19.4±10.1 0.60* 
CrCl (C-G) (min/ml)  73.8±33.2 67.8±19.2 0.08* 
eGFR (MDRD) (ml/min/1.73 m
2
) 96.0±44.8 85.3±20.0 0.01 
CD4+ (cells/mm
3
) 245.9±163.5 391.3±209.5 0.01 
BMI (kg/m
2
) 21±4 22±4 0.03 
Time since HIV diagnosis (years) 2.24±1.7 7.4±4.2 0.01 
Note: - *not significant, Cr= Creatinine, CrCl =Creatinine Clearance, eGFR =estimated Glomerular Filtration 
Rate, MDRD =Modification of Diet and Renal Disease, CD4 =Cluster of Differentiation 4, BMI =Body Mass 
Index, HIV =Human Immunodeficiency Virus, HAART =Highly Active Anti-Retroviral Therapy, SD 
=Standard Deviation  
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6.5. Prevalence of CKD among HIV infected study participants 
The overall prevalence of CKD among HIV infected participants was 13.2% (95%CI 9.2, 
17.6). The prevalence of CKD among HAART naïve study participants was 15.2% (95%CI 
9.6, 20.8), whereas among HAART experienced study participants was 11.2% (95%CI 5.6, 
17.6), p value 0.5. A majority of the CKD cases were observed in CKD stage 2; 28.8% 
HAART naïve and 33.6% HAART experienced. About 34.4% of HAART naïve study 
participants showed urine dipstick proteinuria, whereas less than half (47.2%) of HAART 
experienced study participants showed urine dipstick proteinuria (Table 6).   
Table 6: Prevalence of CKD based on MDRD among HIV infected participants at University 
of Gondar Hospital, Gondar, Northwest Ethiopia, 2017 (N = 250). 
Variables with descriptions  HAART naïve On HAART Total 
No (%) No (%) No (%) 
CKD  
 
<60 Yes   19(15.2) 14(11.2) 33(13.2) 
≥60 No   106(84.6) 111(88.8) 217(86.8) 
Stages 1 ≥ 90 10(8) 12(9.6) 22(8.8) 
2 60-89 36(28.8) 42(33.6) 78(31.2) 
3 30-59.9 18(14.4) 14(11.2) 32(12.8) 
 4 15-29 0(0) 0(0) 0(0) 
5 < 15 1(0.8) 0(0) 1(0.4) 
Proteinuria  No 82(65.6) 66(52.8) 148(59.2) 
Yes 43(34.4) 59(47.2) 102(40.8) 
Note: -Proteinuria ≥ 1+, CKD=Chronic Kidney Disease, MDRD=Modification of Diet and Renal Disease, 
HAART =Highly Active Anti-Retroviral Therapy, HIV =Human Immunodeficiency Virus  
 
 
 
 
22 
 
6.6. Factors Associated with CKD among HIV infected study participants 
Older age ≥50 years (AOR=8.9, 95%CI; 1.2, 68.4) and low CD4 count (<200cells/mm3) 
(AOR=7.6, 95%CI; 1.9, 30.2) were independently associated factors for CKD among 
HAART naïve individuals (Table 7).  
Table 7: Factors associated with CKD among HAART naive HIV infected participants at the 
University of Gondar Hospital, Gondar, Northwest Ethiopia, 2017 (N=125). 
Variables  CKD <60 CKD ≥60 AOR(95%CI) COR(95%CI) P-value 
Yes No 
Age (years) <50
+
 16 103 1   
≥50 3 3 6.4(1.3-37.5) 8.9(1.2-68.4) 0.03* 
Acute kidney injury  No
+
 13 86 1   
Yes
 
6 20 2(0.7-6) 1.9(0.5-7.6) 0.37 
Kidney stone No
+ 
14 100 1   
Yes 6 5 8.6(2-22) 3.6(0.8-15.1) 0.08 
CD4 (cells/mm
3
) <200
 
16 42 8.1(2.2-29.6) 7.6(1.9-30.2) 0.004
**
 
≥200 3 64 1   
Note: - += Reference, * = Significant, ** = highly significant, CD4 = cluster of differentiation 4, CKD 
=Chronic Kidney Disease, Backward stepwise multiple logistic regression was used to assess the independent 
effect of explanatory variables 
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On the other hand, TDF based ART regimen (AOR= 6.0; 95%Cl 1.3-29.4) and CD4 count < 
200 cells/mm
3 
(AOR=18.5; 95%Cl 4.1-83.2) were independently associated with CKD 
among HAART experienced study participants (Table 8).  
Table 8: Factors associated with CKD among HAART experienced at University of Gondar 
Hospital, Gondar, Northwest Ethiopia, 2017 (N=125). 
Factors  CKD <60 CKD 
≥60 
COR(95%CI) AOR(95%CI) P value 
Yes No 
Age (years) <50
+ 
5 85 1   
≥50 9 26 5.8(1.8-19.1) 2.7(0.63-11.7) 0.18 
Diabetes Mellitus No
+ 
12 110 1   
Yes 2 1 18.3(1.5-217.4) 9.1(0.7-125.7) 0.09 
First line regimen  Non TDF
+ 
3 64 1   
TDF 10 46 4.6(1.2-17.8) 6.0(1.3-29.4) 0.025
** 
CD4 (cells/mm
3
) <200
 
10 18 12.9(3.6-45.7) 18.5(4.1-83.2) 0.000
** 
≥200+ 4 93 1   
Note: - + = Reference, ** = highly significant, TDF = Tenofovir Disoproxil Fumarate, CD4 = Cluster of 
Differentiation 4, COR=Crude Odds Ratio, AOR = Adjusted Odds Ratio, CKD =Chronic Kidney Disease, 
Backward stepwise multiple logistic regression was used to assess the independent effect of explanatory 
variables. 
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Both bivariable and multivariable logistic regression analysis showed that older age (≥50 
years), low CD4 count (<200cells/mm
3
) and TDF based ART regimen had statistically 
significant and independently association with CKD among HIV infected study participants. 
Low CD4 count (<200cells/mm
3
) was significantly associated with CKD among HIV 
infected study participants (p-value <0.01). CKD in HIV infected study participants with 
older age ≥50 years was found to be 6 times more likely to develop CKD than those < 50 
years age (AOR=6; 95%CI 2, 12). HIV infected study participants who taken TDF based 
ART regimen were 6 times more likely to develop CKD compared to those non TDF based 
ART regimen users(AOR=6; 95%CI 2, 17). Among HIV infected individuals those who had 
CD4 count <200 cells/mm
3
 were 9 times more likely to develop CKD than CD4 count ≥200 
cells/mm
3
(AOR=9; 95%CI 4, 27) (Table 9). 
Table 9: Factors associated with CKD among HIV infected participants at the University of 
Gondar Hospital, Gondar, Northwest Ethiopia, 2017 (N=250). 
Factors CKD<60 CKD≥60 COR(95%CI) AOR(95%CI) P value  
Yes No 
Age  <50
+
 21 187 1   
≥50 13 29 4(2-8) 6.4(1.9-12.3) 0.028* 
Diabetes mellitus  No
+
 30 209 1   
Yes 4 7 4.1(1.2-15.0) 9.7(0.6-152.9) 0.10 
Kidney stone No
+
 28 204 1   
Yes 6 12 3.6(1.3-10.9) 7.6(0.6-97.0) 0.11 
First line regimen  Non TDF
+
 4 63 1   
TDF 10 46 3.4(2.1-12) 6.3(2.7-17) 0.027* 
Proteinuria  No
+
 10 115 1   
Yes 24 101 2.7(1.2-5.7) 0.2(0.05-1.0) 0.059 
CD4 (cells/mm
3
) <200 27 59 10(4-24) 9(4-27) 0.01** 
≥200+ 7 157 1   
Note: - + = Reference, * = significant, ** = highly significant, TDF = Tenofovir Disoproxil Fumarate, CD4 = 
Cluster of Differentiation 4, COR=Crude Odds Ratio, AOR = adjusted odds ratio, Backward stepwise multiple 
logistic regression was used to assess the independent effect of explanatory variables. 
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7. DISCUSSION 
Renal disease has been documented as a common and closely associated complication of 
HIV infection (38). HIV infected individuals can have many adverse factors which can affect 
the kidney arise from direct effects of HIV such as immune complex disease and HIVAN or 
indirectly from opportunistic infection and drugs (34).  
The prevalence of CKD in all HIV infected study participants in this study based on eGFR 
using the MDRD equation was 13.2% (95%CI 9.2, 17.6). This result is in line with study 
done in  China (16.8%) (16) but lower than study done in northwest of Ethiopia (21.5%) 
(22).  The reason for this could be sample size difference and use of C-G formula for eGFR 
calculation. However, the prevalence of CKD according to current study was higher than 
studies done in Belgium (29) (3%), it was used large sample size with retrospective 
observational analysis but not used proteinuria for definition of CKD, Brazil (30) (8.4%), 
even though, current study similar by sample size with study in Brazil (255) obesity, 
malnutrition and history of kidney disease were excluded by study done in Brazil, Burundi 
(33) (2%), multicenter cross sectional study design and persistence measure for 3 months for 
Cr level and proteinuria was used by study done in Burundi,  sub-Sahara Africa (39) (7%), 
used randomized control trial.  
Therefore, the observed difference may be due to the difference in geographical variation, 
study design, sample size, definition of CKD, exclusion criteria, and measurement of 
proteinuria.  
The prevalence of CKD among HAART naïve study participants was 15.2% (95%CI 9.6, 
20.8). It is consistence with study done in Mainland China (16.1%) (31) and in Kenya 
(11.5%) (40) but much lower than study done in  Kwara state, Nigeria (47.6%) (32) and 
Malawi (21%) (41).  The reason for this variation could be those studies used different 
geographical distribution, and sample size; Nigeria (183), Malawi (526). Moreover, report 
from Malawian used C–G equation for estimated GFR. 
Even though, there was difference in sample size (163 vs 125) used and study design (case-
control vs cross-sectional ) between study done in Ghana (9.9%) and the current study 11.2% 
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(95%CI 5.6, 17.6),  the prevalence of CKD among HAART experience study participants 
was concordant with study done in Ghana (42). On the other hand, this study was lower as 
compared to studies done in Nigeria (23.8%) (43), and in Tanzania (25%) (44).The use of C-
G formula to estimate GFR in Nigeria and Tanzania; furthermore, Nigerian study used 
retrospective study design and the number of study subjects may contribute to the observed 
differences. 
In this study prevalence of proteinuria was (40.8%), (34.4%), and (47.2%) among total study 
participants, HAART naïve, and HAART experienced respectively. This study demonstrates 
high proteinuria when compared with studies done in Mainland China (13.7%) (31), India 
(21%) (45), Malawi (23.3%) (41), Burundi (6.1%) (33), Kenya (12%) (34), northwest 
Ethiopia (Bahir Dar) (17.9%) (22). On the other hand, a similar result was observed in 
Nigeria (41.4%) (19). Sample size, Geographical variation and the use of difference 
measuring technique of proteinuria may contribute for the observed difference. At normal 
physiological condition, small amounts of proteins are seen in the urine since its plasma 
concentration is low. When the glomerular filtration barrier is compromised by disease, an 
increased amount of plasma proteins is allowed to pass into the ultra-filtrate, and glomerular 
proteinuria develops (46).  
Owing to the fact that renal function is known to decline with incline of age, older age is a 
proven risk factor for a decline in CrCl (47). According to this study the observed CKD in 
overall HIV infected study participants, and HAART naïve study participants with age ≥50 
years were more likely to develop CKD than those <50 years age. This result consistence 
with studies done in Belgium, China and Southwest Ethiopia (16, 21, 29). 
The result found from this study showed that low CD4 count (<200 cells/mm
3
) was 
significantly associated with CKD among overall HIV infected, HAART naïve, and HAART 
experienced. A low CD4 count (<200cells/mm
3
) was more likely to develop CKD among 
overall HIV infected, HAART naïve, and HAART experienced study participants. This result 
is in line with a study done in China (16), Nigeria (43), Zambia (48), and southwest (16) and 
northwest Ethiopia (22). In this study the association of CKD with low CD4 cell count may 
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suggest that HIVAN is a contributory cause of CKD in study participants since CD4 cell 
count is used as a surrogate marker of immunological status in HIV infected patients (4). 
This study demonstrated the significant association between CKD with TDF based ART 
regimen among HAART experienced study participants. Being TDF based ART regimen 
user was more likely to develop CKD than non TDF user. Regarding TDF regimen users 
associate with CKD, this is in agreement with findings of studies conducted in New York 
(51), France (52), Netherlands (49), Denmark (12), Japan (50), Brazil (30), and South Africa 
(48). The reason for this association could be the mechanism by which tenofovir causes renal 
toxicity seems to be related to drug accumulation within proximal renal tubules, leading to 
mitochondrial DNA injury, depletion and dysfunction of the oxidative respiratory chain in 
proximal tubular epithelial cells. Therefore, this leads to a depletion of intracellular ATP, 
which limits the proximal tubule’s ability to reabsorb electrolytes and low molecular weight 
proteins (10, 48, 49). 
Generally, the current study indicated that older age (≥50 years), TDF based regimen, and 
low CD4 count (<200cells/mm
3
) were identified as the predictors of CKD in overall HIV 
infected study participants. In addition, older age (≥50 years), and low CD4 count 
(<200cells/mm
3
) were demonstrated as the predictors of CKD in HAART naive study 
participants. Moreover, TDF based regimen users, and low CD4 count were found to be the 
predictors of CKD in HAART experienced study participants. 
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8. LIMITATION AND STRENGTH OF THE STUDY 
In this study creatinine level and proteinuria was measured once so consecutive results could 
not be determined which may be challenging to estimate the presence of CKD due to the 
possibility of reversal causes. As the result of cross-sectional nature of this study, preventing 
assessment of whether risk factors caused or resulted from decreased renal function. 
However, being prospective study, comparison of HAART status, assessment of associated 
factors for CKD could be considered as the strength of this study. 
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9. CONCLUSION 
The overall prevalence of CKD and proteinuria found in this study was high. The results of 
this study indicated that HIV infected adults have high prevalence of CKD among HAART 
naïve than those HAART experienced at the University of Gondar Hospital. The current 
study revealed that a majority of the CKD cases were observed in CKD stage 2; 28.8% 
HAART naïve and 33.6% HAART experienced. Therefore, this study concluded that CKD is 
common in HIV patients. In addition, the current study revealed that those patients who are 
older (≥50 years), have a history of TDF regimen therapy, and low CD4 count (<200 
cells/mm
3
) are factors which can predict the likelihood of developing CKD in HIV infected 
participants. 
10. RECOMMENDATIONS 
 A close monitoring of renal function should be done before and during HAART. 
 Special focus should be given for HIV infected individuals who develop any stages of 
chronic kidney disease in order to get an early treatment before reaching end stage 
renal disease. 
 More strong longitudinal studies should be done to determine risk factors of CKD in 
HIV infected individuals.  
 A result of this study showed that the prevalence of CKD among HIV infected 
individuals was high, so that further studies with large sample size and different study 
design are necessary. Findings from all such studies can be useful for better health 
care planning and delivery. 
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12. ANNEX 
Annex I. English version of patient’s information sheet 
Title of the research project: Prevalence of Chronic kidney disease and associated factors 
among HAART naïve and HAART experienced HIV infected individuals attending at the 
University of Gondar Hospital, Northwest Ethiopia. 
Name of investigator: Shibihon Debebe (BSc, MSc candidate in Clinical chemistry) 
Name of the organization: Department of clinical chemistry, School of Biomedical and 
Laboratory sciences, College of Medicine and health science, University of Gondar. 
Introduction: You are invited to participate as study participant in a research which is going 
to conduct by the indicated MSc candidate from University of Gondar. Your participation is 
voluntarily. The research teams include one principal investigator, sample collectors, 2 
advisors from University of Gondar. Please take as much time as you needed to read or listen 
the information sheet. 
Purpose of the research project: You are requested to take part in this study because we are 
trying to learn more about the prevalence of Chronic kidney disease and associated factors 
among HAART naïve and HAART experienced HIV infected individuals attending at 
University of Gondar Hospital and for better disease management and prevention planning 
and also for providing information to healthcare provider as well as program designers. 
Procedure: In order to perform the indicated study you are invited to take part in this project. 
If you are willing to participate, you need to understand the purpose of the study and give 
your consent then you will be interviewed for the issues and you will give laboratory sample 
related with this study. Laboratory sample include collection of 5 ml of venous blood by 
laboratory technologists for the determination of creatinine, glucose and urea. In addition 15 
ml of urine sample will be collected for determination of urine albumin. The required clinical 
data, socio-demographic data and anthropometric measurements will be collected by 
experienced nurse by using semi-structured questionnaire. It will take about 10-15 minutes to 
fill the questionnaire. 
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Potential risks and discomforts: there are no anticipated risks in participating but you may 
experience small pain during blood collections. 
Potential benefits to subjects and/or community: - Measuring serum creatinine only may 
not provide enough information about the status of the kidney except at end stage renal 
disease, but estimating GFR among suspected patient for CKD such as HIV infected 
individuals important for early diagnosis and for better treatment since it consider age, sex, 
body surface area and race. Thus, the result of the study will be beneficial to know your 
kidney status and associated risk factors and also to get an early treatment before reaching 
end stage renal disease, this also indirectly benefit the community. 
Compensation for participation: - You will not receive any payment for your participation 
in this study. 
Confidentiality: - There is no sensitive issues that you will be asked related with your social 
disability but any information that is obtained in connection with this study and that can be 
identified will remain confidential 
Participation and withdrawal: - You can choose whether to be part of the study or not. You 
may withdraw at any time without consequences of any kind. You may also refuse to give 
any sample and/or information. 
Person to contact: 
If you have any question you can contact use any of the following (investigator and advisors) 
and you may ask at any time you want. 
Shibihon Debebe (BSc, MSc candidate) telephone: 0912356542. 
KetselaYirdaw (MSc), Lecturer at University of Gondar.  
Daniel Asemelash (MSc), Lecturer at University of Gondar. 
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የምርምሩ የአማርኛ ትርጉም አጭር መግሇጫ 
የምርምሩርዕስ-ረዘም ሊሇ ጊዜ የቆየን የኩሊሉት በሽታን መጠንና በሽታውን ሉያመጡ 
የሚችለ ምክኒያቶችን ከኤችአይቪ በሽተኞች ሊይ ማጥናት፡፡ 
የተመራማሪዉ ስም- ሽቢሆን ዯበበ (ባችሇር ሳይንስ ዴግሪ፣የማስተር ዯግሪ እጩ) 
የተቋሙ ስም- ጎንዯርዩ ኒቨርሲቲ ሕ.ጤ.ሳ.ኮ የባዮሜዱካሌ እና ሊቦራቶሪ ሳይነስ ትምህርት 
ክፌሌ፡፡ 
መግቢያ፡- እርስዎ በተጠቀሰው የጎንዯር ዩኒቨርስቲ የማስትርስ ተማሪ ጥናት ሊይ 
እንዱሳተፈ ተጋብዘዋሌ፡፡ የእርስዎ ተሳትፍ በፌቃዯኝነት ሊይ የተመሰረተ ነው፡፡ ጥናቱም 
አንዴ ዋና ተመራማሪ፣ ሁሇት የተመራማሪው እረዲቶችን እና መረጃ ሰብሳቢዎችን ያካተተ 
ነው፡፡ እባከዎን በቂ ሳዓት ወስዯው የምርምሩን መግሇጫ ያንያንቡት፡፡ 
የጥናቱ አሊማ፡-እርስዎ በዚህ ጥናት እንዱሳተፈ የተዯረገበት ምክንያት ረዘምሊሇ ጊዜ የቆየን 
የኩሊሉት በሽታን መጠን እና እንዱሁም በሽታውን ሉያመጡ የሚችለ ምክንያቶችን 
በጎንዯር ዩኒቨርስቲ ኤች አይ ቪ በሽተኞችን ሇማጥናት ነው፡፡ ጥናቱ የሚሠጠውን መረጃ 
መሰረት በማዴረግ ይህ በሽታ የሚያዯርሰውን ተጽኖ ሇመከሊከሌና ህክምና አሰጣጡን 
ሇማሻሻሌ ነው፡፡  
ዝርዝር ተግባራት፡- መጀመሪያ እርስዎ በጥናቱ ሇመሣተፌ ይጠየቃለ፡፡ በጥናቱ ሇመሳተፌ 
ፌቃዯኛ ከሆኑ በሗሊ እርስዎ ጥናቱን በተመሇከተ አንዲነዴ ቃሇ-መጠይቆችን እና የሊቦራቶሪ 
ናሙናዎችን እንዱሰጡን ይጠየቃለ፡፡ 
ቃሇ መጠየቁም ስሇ ጥናቱ በሰሇጠነ የጤና ባሇሙያ (ነርስ) እና የሊቦራቶሪ ናሙዎችን 
ሌምዴ ባሇዉ የሊቦራቶሪ ባሇሙያ ይሰበሰባሌ፡፡ የሊቦራቶሪ ናሙናምዉም 5 ሚሉሉትር ዯም 
እና 15 ሚሉሉትር ሽንት ያካትታሌ፡፡ 
የሚመጡ መጠነኛ ጉዲቶች፡- እርስዎ በጥናቱ በመሳተፌዎ የሚዯርስብዎት አዯገኛ ጉዲት 
የሇም፡፡ ይሁን እንጅ ዯም በሚዎሰዴበት ጊዜ መጠነኛ የሆነ የመርፋ ህመም ስሜት ሉኖር 
ይችሊሌ፡፡ 
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ጥናቱ የሚሰጠው ጠቀሜታ፡- በዯም ውስጥ ያሇውን“ የኬራቲን መጠን መሇካት ብቻውን 
ስሇኩሊሉት ጤንነት ጥሩ የሆነ መርጃ ሇመስጠት አያስችሌም፡፡ ነገር ግን በሽታው 
ያጠቃቸዋሌ ተብል ከሚጠረጠሩ በሽተኞች መካከሌ ሇምሳላ ያክሌ ኤችአይቪ በሽተኞችን 
የኩሊሉት የማጣራት አቅም መሇካት በሽታውን ቶል ሇማወቅ እና የተሸሇ ህክምና ሇማግኘት 
ይርዲሌ፡፡ 
ስሇሆነምጥናቱሉሰጥዎትየሚችሇውዋናጥቅምየኩሊሉትዎትንጤንነትእናይህንበሽታሉያመጡየ
ሚችለትንተጓዲኝምክኒያቶችንሇማወቅይርዲሌ፡፡ ይህ ማሇት በላሊ አነጋገር በማህበረሰቡ 
ከፌተኛ ጥቅም ይሠጣሌ ማሇት ነው፡፡ 
የጥናቱ ተሳታፉ ካሳ፡- አርስዎ በጥናቱ ዉስጥ በመሳተፌዎ ምንም አይነት ክፌያ 
አይሰጠዎትም፡፡ 
የተሳታፉን ሚስጥር ስሇመጠበቅ፡- እርስዎ በጥናቱ ዉስጥ በመሳተፌዎ ምንም አይነት ግሇ-
ስብዕናን የሚነካ መረጃ አይጠየቁም፡፡ ነገር ግን ጥናቱን በተመሇከተ የሚወሰደ መረጃዎችን 
በሚስጥራዊነት ይጠየቃለ፡፡ 
በጥናቱ ስሇመቀጠሌና ስሇማቋረጥ፡- እርስዎ በጥናቱ ሇመሳተፌ በፌቃዯኝነት ተጠይቀዋሌ፡፡ 
ከዚህም ባሻገር እርስዎ በጥናቱ መሳተፌ ና አሇመሳተፌ የሚያስችሌ መብት አሇዎት፡፡ 
የተመራማሪዉ አዴራሻ 
ሽቢሆን ዯበበ፤ የሞባይሌ ቁጥር፡0912356542፣ጎንዯርዩኒቨርሲቲሆስፒታሌ 
የተመራማሪዉ አማካሪዎች አዴራሻ 
ቀፀሊ ይርዲዉ (ማስተርስ ሳይንስ ዱግሪ): ጎንዯርዩኒቨርቲ 
ዲንኤሌ አስመሊሽ (ማስተርስ ሳይንስ ዱግሪ)፡ ጎንዯርዩኒቨርሲቲ 
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Annex II. English version of Study participants consent form 
I the undersigned individual has been well informed about the objectives of the study entitled 
―Prevalence of Chronic kidney disease and associated risk factors among HAART naïve and 
HAART experienced HIV infected individuals attending at the University of Gondar 
Hospital, Northwest Ethiopia’’.  I also informed that all information obtained at any course of 
the study is to be kept confidential. Moreover, I have also been well informed of my right to 
keep hold of, decline to cooperate and drop out of the study if I want and none of my actions 
will have any bearing at all on my overall health care and hospital access. Therefore, with 
full understanding of the situations I agree to give the entire necessary information and blood 
and urine sample for laboratory analysis. 
 
Name………………………………………………          
Signature…………………………………………… 
 
 
የስምምነት ቅፅ የአማርኛ ግሌባጭ 
እኔ ከዚህ በታች የፇረምኩት ጥናቱ በግሌፅ ቋንቋ ተብራርቶሌኝና ተረዴቸ ነዉ፡፡ የጥናቱን 
አሊማ ተረዴቸ ሇተመራማሪዉ አስፇሊጊዉን መጠይቅና የዯም እና ሽንት ናሙና ሇመስጠት 
ተስማምቻሇሁ፡፡ በጥናቱ ሇመሳተፌ የወሰንኩት በራሴ ያሇማንም ተፅዕኖ ሲሆን በማንኛዉም 
ጊዜ ጥቅሜ ሳይጓዯሌብኝ ከጥናቱ መዉጣት እንዯምችሌ ተረዴቻሇሁ እንዱሁም ጥናቱን 
በተመሇከተ የሚወሰዴ መረጃ በሚስጥር እንዯሚያዝ ተነግሮኛሌ፡፡ 
 
 
የጥናቱ ተሳታፉ ስም ..…………… ፉርማ…………….ቀን……………………….  
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Annex III.Questionnaire prepared to assess the prevalence of CKD and associated 
factors among HAART naïve and HAART experienced HIV infected individuals at 
University of Gondar Hospital ART clinic, Northwest, Ethiopia. 
Instruction: Please write and encircle the number in front of the choices that exactly fits the 
status 
Part I. Socio-demographic characteristics 
wo  
Code--------------------------------------- 
 
 
 Question    Response Code  
1 Age  ______ years old  
2 Sex  1. Male 
2. Female 
1 
2 
3 Ethnicity  1. Amhara  
2. Tigre  
3. Oromo 
4. Others------------ 
1 
2 
3 
4 
4 Religion  1. Orthodox Christian 
2. Muslim 
3. Protestant 
4. Others (specify)__________ 
1 
2 
3 
4 
5 Residence 1. Urban 
2. Rural 
1 
2 
6 Current Marital status 1. Single 
2. Married 
3. Widowed 
4. Divorced 
5. Separated 
 
1 
2 
3 
4 
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7 Educational status No education 
2. Primary school  
3. Secondary school  
 4. Higher education  
1 
2 
3 
4 
8 Occupation  
 
1. Housewife 
2. Day laborer 
3. Government worker 
4. Private worker 
5. Merchant 
6. Farmer 
7. Other(specify)______________ 
1 
2 
3 
4 
5 
6 
7 
9  
Level of income per month in 
birr 
 
___________________Ethiopian 
Birr 
 
10 Smoking habit 1. Non- smoker  
2. Current smoker 
3. Ex- smoker 
If you have history of smoking, 
number of cigarettes each 
day___________ 
 
1 
2 
3 
 
11 Have you ever consumed any 
alcohol such as beer, wine, 
spirits ,‖tela‖,‖areki‖ in the last 
1 month? 
1. No 
2. Yes  
If yes, how much do you drink per 
day………………… 
1 
2 
3 
 
12 Do you have sleeping disorder  1. No 
2. Yes  
1 
2 
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Part II. Questions related to clinical & anthropometric measurements 
13 Height in cm  
______cm 
 
14 Weight in Kg  
______kg 
 
 
15 Systolic blood pressure  --------------- mmHg  
16 Diastolic blood pressure ------------------ mmHg  
17 Blood pressure in mmHg __________mmHg  
18 Do you use blood pressure-
lowering medication? 
No  
Yes  
1 
2 
19 Diabetes mellitus  1. Absent  
2. Present  
1 
2 
20 Type of DM Type one 
Type two 
1 
2 
21 Duration of DM ---------------------------  
22 Do you have Family history of 
Kidney disease? 
No 
Yes  
1 
2 
23 Did you get AKI in the past 1. No  
2. Yes  
1 
2 
24 Did you get kidney stone in the 
past  
1. No  
2. Yes  
1 
2 
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25 Duration of HIV after 
diagnosis  
-------------------------------  
26 WHO HIV stage  1. Stage I         
2. Stage II         
3. Stage III 
4. Stage  IV 
 
1 
2 
3 
4 
27 Duration of ARV treatment  ----------------------  
28 Antiretroviral regimen  1. First line regimen 
2. Second line regimen 
3.  
 
Interviewer name _________________________Signature________date__________ 
Thank you very much for your participation!!  
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ቃሇ-መጠይቅ 
ይህ ቃሇ መጠየቅ የተዘጋጀው ረዘም ሊሇ ጊዜ የቆየን የኩሊሉት በሽታን መጠንና በሽታውን 
ሉያመጡ የሚችለ ምክኒያቶችን በጎንዯር ዩኒቨርስቲ ሆስፒታሌ የኤችአይቪ በሽታ 
በሚታከሙ እና ሇመታከም በሚመጡ በሽተኞች ሊይ ሇማትናት ነው፡፡ 
እባክዎት እርስዎን የሚወክሇውን አማራጭ ያክብቡ ( በጽሁፌ ይግሇጽሌን)፡፡ 
I. አጠቃሊይ ማህበራዊ መረጃ መጠይቅ 
ተ.ቁ  
የሚስጥርቁጥር--------------------------------------- 
 
 
 
ጥያቄ መሌስ Code  
1 እዴሜ ______     ዓመት  
2 ፆታ 1. ወንዴ 
2. ሴት 
1 
2 
3 ብሄርዎ 1. አማራ 
2. ትግሬ 
3. ኦሮሞ 
4. ላልች 
 
4 ሀይማኖትዎ ኦርቶድክስ 
ሙስሉም 
ፕሮቴስታንት 
ላልች 
1 
2 
3 
4 
 
5 የመኖሪያ አካባቢዎ 1. ከተማ 
2. ገጠር 
1 
2 
6 የጋብቻ ሁኔታዎ 1. ያሊገባ 
2. ያገባ 
3. የሞበት/ባት 
4. የተፊታ/ች 
 
1 
2 
3 
4 
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7 የትምህርት ዯረጃዎ ያሌተማረ 
2. የመጀመሪያ ዯረጃ ያጠናቀቀ 
3. ሁሇተኛ ዯረጃና ከዚያ በሊይ 
 4ከፌተኛ የትምህርት ዯረጃና ከዚያበሊይ 
1 
2 
3 
4 
 
8 የስራ ሁኔታዎ 
 
የቤት እመቤት 
የቀን ሰራተኛ 
የመንግስት ሰራተኛ 
የግሌ ስራ 
ነጋዳ 
ገበሬ 
ላልች (ይግሇዑ)…………… 
1 
2 
3 
4 
5 
6 
 
7 
9 የወር ገቢዎ በብር …………………….ብር  
10 ሲጋራ ያጨሳለ? 1. አሊጨስም 
2. አጨሳሇሁ 
3. አቋርጫሇሁ 
ሲጋራ አጭሰዉ የሚያውቁ ከሆነ 
በቀን ምን ያክሌ ያጨሳለ?_______ 
1 
2 
3 
 
11 አሌኮሌ መጠጥ (ቢራ ÷አረቀ-
÷ ጠሊ÷ ጠጂ÷ ላልችም ) 
ይጠጣለ? 
አሌጠጣም 
አዎ 
መሌስዎ አዎ ከሆነ በቀን ምን ያክሌ 
ይጠጣለ? _______ 
 
1 
2 
 
12 የእንቅሌፌ መዛባት በሽታ 
ገጥመዎት ያዉቃለ? 
1. የሇም 
አዎ 
1.  
1 
2 
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II. የከሉኒካሌና አንትሮፖሜትሪክ ሌኬታን የሚመሇከት መጠይቅና ሌኬታ 
13 ቁመት በሴንቲሜትር _______________ሴንቲሜትር  
14 ክብዯት በኪልግራም ______________ኪልግራም 
 
 
15 ሲይስቶሉክ የዯም ግፉት ------------------------------ሚሉሜትርሜርኩሪ  
16 ዲይስቶሉክ የዯም ግፉት ------------------------------ሚሉሜትርሜርኩሪ  
17 የዯም ግፉት በሚሉሜትር ሜርኩሪ __________ሚሉሜትርሜርኩሪ  
18 የግፉት መዲኒት ይወስዲለ? አሌወስዴም 
1. አዎ 
1 
2 
19 ስኳር በሽታ አሇበዎት 2. አይዯሇም 
አዎ 
1.  
1 
2 
20 የስኳር በሽታው አይነት 1.አንዯኛው አይነት 
2.ሁሇተኛው አይነት 
1 
2 
21 የስኳር በሽታ ከያዘወት ምን ያክሌ 
ጊዜ ሆነዎት? 
__________  
22 ከቤተሰብዎት መካከሌ የኩሊሉት 
በሽታ ታሞ የሚያውቅ አሇ? 
የሇም 
አዎ 
1 
2 
23  ፇጣን የኩሊሉት በሽታ ታመዉ 
ያውቃለ? 
የሇም 
አዎ 
1 
2 
24 የኩሊሉት ጠጠር ታመዉ 
ያዉቃለ? 
1. የሇም 
አዎ 
1 
2 
47 
 
25 ኤችአይቪ በዯሞ ዉስጥ መኖሩን 
ካውቁ ምን ያህሌ ግዜ ሆኖዎት? 
2. ----------------  
26 የአሇም አቀፌ የጤና ዴርጅት 
ኤችአይቪ ዯረጃ 
1. ዯረጃ 1 
2. ዯረጃ 2 
3. ዯረጃ 3 
4. ዯረጃ 4 
1 
2 
3 
4 
27 የኤችአይቪመዴሃኒትመዉሰዴከጀመ
ሩምንያህሌግዜሆኖዎት?  
---------------  
28 የሚወስደት የመዴህኒት አይነት 
ምን አይነት ነዉ? 
  
ቃሇመጥቁን ያስሞሊዉ ስም____________ፉርማ ____________ቀን_________ 
 
ሊዯረጉሌን ተሳትፍ እጅግ በጣም እናመሰግናሇን !!! 
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Annex IV. Check list for exclusion criteria of study participants 
The patients who fulfilled the following characteristics were excluded from the study  
1. Was the patient pregnant? A. Yes    B. No 
2. Was the patient amputee?    A. Yes      B. No 
3. Was the patient years < 18 and >65? A. Yes      B. No 
Annex V. Laboratory procedures for blood and urine specimen collection and 
processing 
I. Procedures for blood specimen collection and processing 
Blood samples was taken from subjects by vein puncture into sterile clinical chemistry tubes 
with serum separator gel.  
1) A sterile, dry 5ml plastic syringe was selected and attached to an appropriate needle.  
2)  A tourniquet wastied on the upper arm of the patient and was asked to make a fist. 
3) Cotton wool soaked in 70% alcohol wasused to clean (sterilize) the skin for vein 
puncture. 
4) Vein puncture was made with the bevel of the needle appropriately angled. A steady 
withdrawal of the plunger of the syringe was very necessary to prevent injuring the vein. 
5)  About 5mls of blood was collected before tourniquet was removed. 
6) The needle was removed carefully and the puncture site pressed with a piece of cotton 
wool to stop bleeding.  
7) The needle from the syringe was carefully disposed off properly. 
8) The site of vein puncture was inspected for bleeding. A piece of cotton wool was placed 
on the site and a plaster placed on it. 
9) The blood was transferred to the test tube. 
10) The sample was allowed to stand to clot and centrifuge at 3000-5000rpm for 5 minutes. 
11) Serum sample was separated and placed in neck tube, stored at -200c until processing 
(50). 
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II. Procedures for Urine specimen collection and processing 
1. 15 ml of freshly voided urine was collected by clean,dry container. 
2. The container was labeled by patient code. 
3. Within 30 minute of collection the reagent area of the strip was dipped briefly into the 
specimen. 
4. Excess urine was removed by tapping or drawing the edge of the strip along the rim of 
the urine container. 
5. The color wascompared that developed with the color chart supplied by the manufacturer 
and report as indicated on the chart. 
Annex VI. Laboratory methods, principles and procedures to determine biochemical 
tests 
Chemical Jaffe reaction method to determine serum creatinine 
In the Jaffe reaction, creatinine reacts with picric acid in an alkaline environment to generate 
an orange-red product and the intensity of color generated is directly proportional to 
creatinine concentration. The absorbance was read at wave length of 490-500nm according to 
manufacturer manual. The result was reported in mg/dl. 
Creatinine +picric acid     alkaline environment orange-red product 
Chemical method to determine Urea 
Urea in sample reacts directly with reagent called diacetylmonoxime which cause a color 
change that can be spectrophotometrically measured at 540nm and the increase intensity of 
the color is directly proportional to the amount of urea in the sample .The result was reported 
in mg/dl. 
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Colorimetric reagent strip (dipstick) test for urine protein detection 
It is based on the ability of albumin to alter the color of some acid-base indicators without 
altering the P
H 
.when an indicator, such as tetra bromophenol blue is buffered at p
H 
3, it is 
yellow in solution without albumin but it was blue in the presence of increasing amount of 
albumin. The result was reported qualitatively. 
CD4 count 
Principle: - When whole blood is added to the reagents, fluorochrome - labeled antibodies in 
the reagents bind specifically to lymphocyte surface antigens, and a fluorescent nuclear dye 
binds to the nucleated blood cells. After a fixative solution is added to the reagent tubes, the 
sample is run on the instrument. During sample acquisition, the cells come in contact with 
the laser light, which causes the fluorochrome-labeled cells and fluorescently dyed cells to 
fluoresce. This fluorescent light provides the information necessary for the instrument to 
identify and count the lymphocytes and CD4 lymphocytes. In addition, the reagent tubes also 
contain a known number of fluorescent reference beads. A precise volume of whole blood is 
stained directly in the reagent tube. The software automatically identifies lymphocyte 
populations and calculates the CD4 counts (cells/mm
3
) by comparing cellular events to bead 
events and result printed immediately after sample was run. 
Procedures: 
1. The tab of each reagent tube was labeled with the patient accession number or number 
that identifies the tube of blood.  
2. Each tube was vortexed upside down for 6 seconds and upright for 6 seconds.  
3. Each reagent tube was opened with the coring station.  
4. EDTA blood tube was mixed (vortexed) for 5 to 10 times to make sure that the whole 
blood was adequately mixed  
5. 50μl of whole blood was pipetted into the labelled reagent tube with the corresponding 
patient accession number.  
6. The tube was caped and vortexed upright for 6 seconds and incubate for 30 minutes in the 
working station.  
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7. Each sample tube was uncapped and pipetted by 50μl of fixative solution into each tube.  
8. The sample tubes was run on the BD FACS Count instrument within 48 hours of adding 
fixative. 
Anthropometric and Blood pressure measurement 
Anthropometric measurement (weight, height) was measured according to WHO guidelines 
by trained nurses (51). Height was measured to the nearest 0.5cm using standio-meter and 
weight was recorded to the nearest 0.1kg with the patient being bare footed and wearing light 
clothes using a balance. From weight and height measurements BMI was calculated as 
weight divided by height squared (kg/ m
2
). Underweight, Normal weight, overweight and 
obesity was defined as a BMI<18.5 kg/m
2
, 18.5- 24.9 kg/m
2
, 25-29.9 kg/m
2
 and ≥30 kg/m2, 
respectively. 
Blood pressure was taken by qualified personnel using an analogue sphygmomanometer and 
stethoscope. Measurements were taken from the upper arm with the hand at the heart level 
after the patient had been sitting for more than 5 minutes. Systolic blood pressure ≥140 
mmHg and/or diastolic blood pressure ≥90 mmHg or current use of blood pressure-lowering 
medication was used to define hypertension. 
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